Indeed, CIK therapy promotes intracellular adhesion and combination by expressing CD56 molecules and can release perforin, cytolysin, etc., to induce osmotic dissolution of target cells, is not likely to elicit graft-versus-host disease, and typically causes only mild adverse reactions such as fever (14, 15). Here, PRF1 is linked to graft versus host disease.